135 related articles for article (PubMed ID: 12833655)
21. Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome.
Ding C
Curr Opin Investig Drugs; 2006 Nov; 7(11):1020-5. PubMed ID: 17117592
[TBL] [Abstract][Full Text] [Related]
22. Emerging biologic drugs for the treatment of rheumatoid arthritis.
Puppo F; Murdaca G; Ghio M; Indiveri F
Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
[TBL] [Abstract][Full Text] [Related]
23. RDP-58 (SangStat Medical).
Holtmann MM
IDrugs; 2003 Dec; 6(12):1188-94. PubMed ID: 14666431
[TBL] [Abstract][Full Text] [Related]
24. Etanercept (Enbrel) -- an update.
Goffe B
Skin Therapy Lett; 2004 Dec-2005 Jan; 9(10):1-4, 9. PubMed ID: 15657632
[TBL] [Abstract][Full Text] [Related]
25. Are selective COX-2 inhibitors as effective as NSAIDs in patients with rheumatoid arthritis?
Smucny J; Chai G
Am Fam Physician; 2004 Feb; 69(3):595-6. PubMed ID: 14971842
[No Abstract] [Full Text] [Related]
26. [New biological therapeutic options for the treatment of RE: inhibition of costimulatory molecules and blockade of Interleukin-6-interaction].
Perniok A; Rubbert-Roth A
Z Rheumatol; 2003 Oct; 62(5):433-8. PubMed ID: 14579030
[TBL] [Abstract][Full Text] [Related]
27. SPM-927 (Schwarz Pharma).
Hovinga CA
IDrugs; 2003 May; 6(5):479-85. PubMed ID: 12789603
[TBL] [Abstract][Full Text] [Related]
28. An excellent example of an early arthritis clinic -- what is its clinical value?
Sokka T; Mäkinen H
J Rheumatol; 2009 Jul; 36(7):1355-6. PubMed ID: 19567630
[No Abstract] [Full Text] [Related]
29. M-40403 Metaphore Pharmaceuticals.
Di Napoli M; Papa F
IDrugs; 2005 Jan; 8(1):67-76. PubMed ID: 15650944
[TBL] [Abstract][Full Text] [Related]
30. A randomized, open-label, comparative, 6-month trial of oral ultra-low doses of antibodies to tumor necrosis factor-alpha and diclofenac in rheumatoid arthritis.
Dugina JL; Petrov VI; Babayeva AR; Martyushev-Poklad AV; Tcherevkova EV; Epstein OI; Sergeeva SA
Int J Tissue React; 2005; 27(1):15-21. PubMed ID: 15847101
[TBL] [Abstract][Full Text] [Related]
31. Is IL-1 a good therapeutic target in the treatment of arthritis?
Burger D; Dayer JM; Palmer G; Gabay C
Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):879-96. PubMed ID: 16980212
[TBL] [Abstract][Full Text] [Related]
32. Technology evaluation: ING-1, XOMA.
Lewis LD
Curr Opin Mol Ther; 2003 Aug; 5(4):433-6. PubMed ID: 14513688
[TBL] [Abstract][Full Text] [Related]
33. PVAC (Corixa/Genesis/Medicis).
Leopold CS; Maibach HI
Curr Opin Investig Drugs; 2002 Nov; 3(11):1604-7. PubMed ID: 12476960
[TBL] [Abstract][Full Text] [Related]
34. [Effect of Tripterygium Wilfordii Hook T4 monomer on proliferation and interleukin-6 production of synovial fibroblasts of patients with rheumatoid arthritis].
Guo Y; Yu M; Jiang Y; Song Q; Dong Y
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Apr; 22(2):190-2. PubMed ID: 12903526
[TBL] [Abstract][Full Text] [Related]
35. BiP regulates autoimmune inflammation and tissue damage.
Panayi GS; Corrigall VM
Autoimmun Rev; 2006 Feb; 5(2):140-2. PubMed ID: 16431346
[TBL] [Abstract][Full Text] [Related]
36. Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis.
Camp NJ; Cox A; di Giovine FS; McCabe D; Rich W; Duff GW
Genes Immun; 2005 Sep; 6(6):467-71. PubMed ID: 15931231
[TBL] [Abstract][Full Text] [Related]
37. Tetomilast.
O'Mahony S
IDrugs; 2005 Jun; 8(6):502-7. PubMed ID: 15906198
[TBL] [Abstract][Full Text] [Related]
38. [Interactions of nonsteroid anti-inflammatory drugs with inhibitors of angiotensin-converting enzyme in patients with rheumatic diseases (a review)].
Tsurko VV; Preobrazhenskiĭ DV; Ob ukhova OA
Ter Arkh; 2003; 75(5):64-70. PubMed ID: 12847902
[No Abstract] [Full Text] [Related]
39. Lerisetron. FAES.
Huckle R
Curr Opin Investig Drugs; 2003 Jul; 4(7):874-7. PubMed ID: 14619411
[TBL] [Abstract][Full Text] [Related]
40. VX-745. Vertex Pharmaceuticals.
Haddad JJ
Curr Opin Investig Drugs; 2001 Aug; 2(8):1070-6. PubMed ID: 11892915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
